Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors
April 11 2018 - 8:00AM
Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage,
women’s biopharmaceutical company, today announced the
appointment of Jessica Grossman, M.D., to its board of directors.
Dr. Grossman is currently the CEO of Medicines360, a global
nonprofit women’s health pharmaceutical company that developed the
FDA-approved contraceptive IUS LILETTA® (levonorgestrel-releasing
intrauterine system).
“We are excited to add Dr. Grossman to our highly distinguished
board of directors,” said Sabrina Martucci Johnson, CEO of Daré
Bioscience. “Dr. Grossman brings a deep understanding of women’s
health along with relevant experience in product development,
partnering and commercialization.”
Prior to her appointment as CEO of Medicines360, Dr. Grossman
served as President and Founding CEO of Sense4Baby, Inc., which
developed an innovative, wireless maternal fetal heart rate
monitoring system for women with high-risk pregnancies. Dr.
Grossman was also Founder and President of Gynesonics, Inc., an
early-stage medical device company focused on minimally invasive
solutions for women’s health, which developed the first
intrauterine, ultrasound-guided radiofrequency ablation device for
fibroid tumors.
“I am pleased to join the Daré board of directors,” said Dr.
Grossman. “I believe that Daré is at the leading edge of
innovation, and I’m looking forward to helping the company deliver
on its mission and vision to identify and address unmet needs in
women’s sexual and reproductive health.”
Dr. Grossman earned a Medical Degree from Sidney Kimmel Medical
College at Thomas Jefferson University in Philadelphia and an
undergraduate degree with honors from Brandeis University. In
addition to her academic and professional accreditations, she has
also performed research at the Beth Israel Deaconess Medical
Center, part of the Harvard Medical School system.
About Medicines360
Medicines360, located in San Francisco, California, is a
nonprofit global women’s health pharmaceutical company with a
mission to expand access to quality medicines for all women
regardless of their socioeconomic status, insurance coverage or
geographic location. Medicines360 is committed to working with
healthcare providers, advocacy groups and patients to deliver
innovative and meaningful treatments that help women around the
world have greater access to the medicines they need. For more
information, visit www.medicines360.org.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s reproductive health that address
clear therapeutic gaps. The company is driven by a mission to
identify, develop and bring to market a diverse portfolio of novel
and differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women, primarily in the
areas of contraception, vaginal health, sexual health and
fertility. Daré currently has two product candidates in clinical
development. The first is Ovaprene™, a non-hormonal monthly
contraceptive ring intended to provide protection over multiple
weeks between menses. The second is SST-6007 (5% Topical Sildenafil
Citrate Cream), a potential treatment for Female Sexual Arousal
Disorder. SST-6007 incorporates sildenafil, the same active
ingredient in Viagra®, in a proprietary cream formulation that is
specifically designed to locally increase blood flow to the
vulvar-vaginal tissue in women, leading to a potential improvement
in genital arousal response and overall sexual experience. Daré
also has an option to enter into a license agreement for ORB-204
and ORB-214, preclinical stage injectable etonogestrel
contraceptives with target 6- and 12-month durations.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of The Private Securities Litigation
Reform Act of 1995 regarding matters that are not historical facts,
including statements relating to Daré's ability to develop Ovaprene
and Topical Sildenafil at the cost and in accordance with the
targeted timelines and milestones set forth herein, expectations
regarding the anticipated market demands for its products, the
safety and effectiveness of its products, market acceptance of
Daré's products and the qualifications and expertise of Daré's
management team. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements as a result
of various important factors, including the uncertainties inherent
in the initiation and completion of clinical trials; availability
and timing of data from ongoing and future clinical trials and the
results of such trials; whether preliminary results from a clinical
trial will be predictive of the final results of that trial or
whether results of early clinical trials will be indicative of the
results of later clinical trials, expectations for regulatory
approvals; claims of infringement and other risks relating to
Daré's owned and licensed intellectual property rights, and other
factors discussed in the "Risk Factors" section of Daré's Report on
Form 10-K filed with the Securities and Exchange Commission on
March 28, 2018. Additional information concerning factors that
could cause actual results to materially differ from those in the
forward-looking statements is contained in Daré's reports to the
Securities and Exchange Commission, including Daré's reports on
Forms 10-Q, 8-K and 10-K. In addition, any forward-looking
statements included in this press release represent our views only
as of the date of this release and should not be relied upon as
representing our views as of any subsequent date. Daré specifically
disclaims any obligation to update any forward-looking statements
included in this press release.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Ami
BavishiBurns McClellanabavishi@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:Amanda
GuisbondCanale Communicationsamanda@canalecomm.com781-405-8775
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024